Recent evidence suggests that cardiac progenitor cells (CPCs) may improve cardiac function after injury. The underlying mechanisms are indirect, but their mediators remain unidentified. Exosomes and other secreted membrane vesicles, hereafter collectively referred to as extracellular vesicles (EVs), act as paracrine signalling mediators. Here, we report that EVs secreted by human CPCs are crucial cardioprotective agents.
Introduction
Ischaemic heart disease and ensuing heart failure are leading causes of morbidity and mortality worldwide. An extensively investigated approach for ischaemic heart disease is cell transplantation. Multiple cell sources including bone marrow, 1 adipose tissue, 2 skeletal myoblasts, 3 and cardiac progenitor cells (CPCs) 4 have been evaluated in both animal models and humans. Clinical trials of autologous BM cell transplantation in patients after acute myocardial infarction (MI) have provided mixed results, with an overall modest improvement in cardiac function. 5 Intramyocardial injection of CPCs isolated from adult hearts improved cardiac function in animal models of MI. 6 -8 Although both direct cell differentiation and indirect mechanisms, such as secreted growth factors and cytokines, have been implicated in the therapeutic benefit, accumulating evidence suggests predominant roles of the paracrine secretion by CPCs. 8 This concept is supported by the observation that CPC-conditioned medium (CM) protects cardiomyocytes against stress-induced apoptosis, while stimulating tube formation in endothelial cells in vitro. 8 -11 The CADUCEUS trial of cardiosphere-derived cells has shown that some degree of cardiac regeneration in injured hearts may be possible. The mechanism of benefit was thought to be indirect. 4 A key component of paracrine secretion in many cell types are extracellular vesicles (EVs), particularly its exosomal fraction. Exosomes are 40-90 nm-sized particles stored intracellularly in endosomal compartments, which are secreted when these structures fuse with the plasma membrane. 12, 13 Conventional surface markers of exosomes include the tetraspanin family members, CD9, CD63, and CD81, among others. Exosomes carry proteins, lipids, and nucleic acids including DNA, mRNAs, and microRNAs (miRNAs), which they can shuttle to recipient cells, even at a distance. miRNAs are 18-25 nucleotide, non-coding RNAs that regulate gene expression through post-transcriptional repression.
Transfer of mRNAs and miRNAs through exosomes has emerged as a crucial mechanism of genetic exchange between cells. 14, 15 Non-exosomal
EVs arise by distinct mechanisms including direct budding from the plasma membrane. While non-exosomal EVs are typically larger than exosomes, exosome purification remains a challenging task. As a result, exosomal preparations used in many studies showed limited purity. 16 Exosomes were identified as the active component of the proangiogenic paracrine activity of bone marrow CD34 + stem cells. 17 Moreover, exosomes secreted by mesenchymal stem cells (MSCs) and mouse CPCs mitigated tissue damage and ventricular remodelling in animal models of myocardial ischaemia and reperfusion injury. 18, 19 However, exosomes secreted by human CPCs have not been characterized yet.
Using transmission electron microscopy, we recently provided ultrastructural evidence of exosomes and EVs secretion by human CPCs. 20 Here, we report that EVs are the active component of the paracrine secretion by human CPCs. Transmission electron microscopy and nanoparticle tracking analysis showed most EV secretion by CPCs to be 30-90 nm in diameter, suggesting they were exosomes, although smaller and larger vesicles were also present. Moreover, the purified particles expressed conventional exosomal markers including CD63. These results suggest that exosomes were the predominant component of the particles purified from CM-CPC. To stress their heterogeneity, however, we hereafter refer to them as EVs. These EVs mitigated apoptosis triggered by serum deprivation in the neonatal mouse HL-1 cardiomyocytic cell line, while stimulating tube formation in human umbilical vein endothelial cells (HUVECs), an indicator of angiogenic activity. In vivo, injection of EVs secreted by CPCs into the infarct border zone reduced cardiomyocyte apoptosis and scar, increased both viable mass in the infarct area and blood vessel density, and prevented the early impairment of ventricular function in a rat model of acute MI. EVs secreted by normal human dermal fibroblasts (NHDFs) lacked these beneficial effects, supporting the concept that functional activities of EVs depend on the parent cell. 17 A comparison of the miRNA transcriptional profile of EVs secreted by CPCs with that of EVs secreted by NHDFs identified several miRNAs as being particularly enriched in the former, including miR-210, miR-132, and miR-146a-3p. Because cardioprotective roles of miR-210 and a role for miR-132 in vascular remodelling have been reported, 21, 22 we focused on the functional activities of these miRNAs. Both miR-210 and miR-132 protected HL-1 cardiomyocytic cells against apoptosis. In addition, miR-132 promoted the formation of endothelial tube. These results suggest that EVs secreted by CPCs may impart cardiac protection and the underlying mechanism may involve miRNAs.
Methods

Cell sources
Human right atrial appendage specimens were obtained from patients (n ¼ 22) who underwent surgical repair of heart valve disease and had no concomitant coronary artery disease. The study was approved by the local Ethical Committee and performed according to the Declaration of Helsinki. All patients gave written informed consent to the collection of atrial specimen. Using the primary ex vivo tissue culture technique, 6 -8 the cellular outgrowth of atrial explants was collected within 14 days and seeded into fibronectin-coated 25 mL flasks. EVs were purified from CPCs after two passages in culture. NHDFs were purchased from Life Technologies.
EV purification methods
Medium conditioned by CPCs (CM-CPC) or NHDFs was obtained by culturing cells in basal medium (BM), a 1 : 1 mix of Iscove's Modified Dulbecco's Media and Dulbecco's Modified Eagle's Medium (Gibco) supplemented with 1% human serum albumin, for 48 h, followed by centrifugation at 3000 g for 15 min, filtration through a 0.2 mm membrane (BD Biosciences), and processing using one of the following methods: (i) ExoQuick TM precipitation solution (System Biosciences; SBI); (ii) ultracentrifugation at 100 000 g for 90 min; and (iii) column precipitation using Exo-spin TM kits (Cell Guidance Systems, Cambridge, UK). The EV pellet was re-suspended in 100 -500 mL of phosphate-buffered saline (PBS; pH 7.4) and stored at 2808C. Nanoparticle tracking analysis was performed using NanoSight LM10 (Malvern Instruments, Worcestershire, UK). CD63 and CD81 protein levels in EVs were determined by western blotting. Protein lysate was obtained by re-suspending EV pellet in 100 mL of RIPA buffer (Sigma). Antibodies were purchased from SBI. Total proteins were measured using BCA kits (Thermo Fisher Scientific).
Transmission electron microscopy
The ultrastructure of EVs was analysed using transmission electron microscopy, as described previously. 23 Briefly, re-suspended EV pellet (3 mL) was fixed with 2.5% glutaraldehyde, post-fixed in buffered 1% OsO 4 with 1.5% K 4 Fe(CN) 6 , embedded in 1% agar, and processed according to the standard Epon812 embedding procedure. EVs were visualized on thin sections (60 nm) using a Morgagni 268 transmission electron microscope (FEI Company, The Netherlands) at 80 kV.
Flow cytometry
Surface markers expressed on CPCs and EVs were analysed by flow cytometry. Microbeads coated with anti-CD63 antibody (Life Technologies) were used in EV analyses. Phycoerythrin (PE)-conjugated antibodies against surface markers expressed on CPCs or MSCs (CD90, CD105, CD140, CD146, CD166, CD172, and NG2 proteoglycan; all from Beckman Coulter) or conventional exosomal markers (CD9, CD63, and CD81; all from BD Biosciences) were used. Beads incubated with an antibody in the absence of EVs served as a control. To assess dynamic trafficking of CD63 to exosomes, CPCs were transfected with pCT-CD63-GFP vector (CytoTracer; SBI) expressing a CD63-GFP fusion, using lipofectamine. Analyses were performed on a MACS-Quant flow cytometer (Miltenyi Biotec).
EV uptake by HL-1 cardiomyocytic cells
To assess EV uptake by HL-1 cardiomyocytic cells, EVs from CPCs were labelled with DiI. Excess dye was removed by precipitation of EV. Cells cultured in complete Claycomb medium 24 (Sigma), hereafter referred to as growth medium (GM)-FBS, were incubated with DiI-labelled EVs. After 12 h, cells were imaged using a Nikon C2 Plus confocal microscope. RNA
Human exosomes preserve cardiac function after MI extraction, reverse transcription, and real-time PCR protocols were used as described in Supplementary material online, to determine intracellular concentrations of miR-210 and miR-132 in HL-1 cells exposed to EV-CPC. In the time-course experiment, 100 mg of EV-CPC total protein were used (n ¼ 3 experiments). Dose-response study measurements were performed at 48 h (n ¼ 3 experiments).
In vitro apoptosis assay
To induce apoptosis in the mouse HL-1 cardiomyocytic cell line, GM-FBS was replaced by BM for 12 h. After 12 h, medium was supplemented with CM-CPC, EV-depleted CM-CPC (DCM), or DCM reconstituted with the previously removed EV fraction (DCM + EV) for 36 h. Cells kept in BM for 48 h or changed to GM-FBS after 12 h served as controls. A pooled sample of purified EVs secreted by CPCs (EV-CPC; n ¼ 4 patients) was compared with EVs secreted by NHDF (EV-F). Viable and dead cells were stained using double staining kits (Dojindo EU GmbH, Germany). Activation of apoptotic pathways was detected using activated caspase-3/7 staining kits (Life Technologies).
In vitro angiogenesis assay
To assess the angiogenic potency of CM-CPC, EV-CPC, and EV-F, HUVECs were seeded at 3 × 10 4 cells/cm 2 density in Matrigel (BD Biosciences). An endothelial cell medium (Medium 200; Gibco) supplemented with 10% FBS (ECM-FBS) served as a positive control. Images were acquired 5 h later, and tube length was measured using the ImageJ software (National Institutes of Health, USA).
miRNA analyses
Total RNA was isolated from EV-CPC and EV-F using Quanti-miR kits (SBI). Real-time PCR was performed with Advanced SYBR Green kits (Bio-Rad) using a multistep approach. In a first step, 384 miRNAs were measured in total RNA from a pooled EV-CPC sample (n ¼ 4 patients) using synthetic 'spike-in' miRNA sequences, provided with the kits for normalization. Fifty-two miRNAs were found to be enriched more than six-fold compared with 'spike-in' miRNA sequences. In the following step, these miRNAs were directly compared with EVs from CPCs and those from NHDFs. Fourteen miRNAs were found to be particularly enriched in EVs from CPCs. These miRNAs were then measured in three pooled EV-CPC samples (n ¼ 4 patients each). Based on the results of this analysis, 7 of 14 miRNAs were then measured in EV-CPC samples from individual patients (n ¼ 6). Data were normalized for the geometric mean of miR-U6 and RNU-6B values and shown as 2 2DDCt values. Among the most highly enriched miRNAs in EVs secreted by CPCs, miR-210 and miR-132 were chosen for functional studies, owing to their proposed roles in cardioprotection and vascular remodelling. 21, 22 Cells were transfected with miR-210 and miR-132 mimics, or siRNAs specific for these miRNAs, using RNAiMAX TM (Life Technologies). Expression of the miR-210 targets, ephrin A3, PTP1b, and FLASH/CASP8AP2, 21, 25, 26 as well as those of miR-132 target, RasGTPase-activating protein (RasGap)-p120, 22 was measured by western blot using antibodies from Santa Cruz Biotech.
In vivo myocardial infarction
Experimental protocols were approved by the Animal Care Committee of the Italian Ministry of Health, in accordance with Italian (DL-116, 27 January 1992) and international laws and policies (European Economic Community Council Directive 86/609, OJL 358, 12 December 1987). Animal studies were performed as previously described. 27 Briefly, acute MI was induced in healthy male Wistar rats (250 -300 g body weight), anaesthetized with a cocktail of tiletamine and zolazepam (Zoletil 100, Virbac, France; dosage 40 mg/kg IP), intubated, and ventilated. The left anterior descending coronary artery was permanently ligated near its origin with a 6-0 Prolene suture. After 60 min, the viable myocardium bordering the LV infarct zone was injected at three different sites with a total of 150 mL of one of the following solutions: PBS (n ¼ 9), 30 mg of EV-CPC (n ¼ 9), 300 mg of EV-CPC (n ¼ 10), and 300 mg of Exo-F (n ¼ 4). The sham-operated group included nine animals. At Day 7, rats were anaesthetized with Zoletil 100 (40 mg/kg) and sacrificed with iv KCl (1 -2 mEq/kg) to induce diastolic arrest of cardiac activity.
Echocardiography
Echocardiography was performed in rats sedated by IP tiletamine (29 mg/kg) plus xylazine (4.3 mg/kg). Transthoracic echocardiography was performed on Day 2 (baseline) and Day 7 post-MI using the MyLab 30 echocardiography system (Esaote, Italy), equipped with a 12 MHz linear transducer, as described previously. 28 Under electrocardiographic monitoring of heart rate, the hearts were imaged in 2D long-axis views at the level of the highest LV diameter. LV end-diastolic and end-systolic diameters (LVEDD/ LVESD), end-diastolic wall thickness (LVEDTHK-BZ) and end-systolic wall thickening in the border zone (LVESTK-BZ), and LV ejection fraction (LVEF) were measured from 2D long-axis views taken through the infarcted area. Changes in LVEF were calculated as LVEF (Day 7) 2 LVEF (baseline)/ LVEF (baseline).
Histology
Rats were sacrificed at Day 7 after MI. For immunohistochemistry, hearts were cryopreserved in optimal cutting temperature compound (Sigma) at 2808C. For morphometry, they were embedded in paraffin and cut at 8 mm thin sections. Apoptotic cardiomoycytes were detected by TUNEL assay using In Situ Cell Death Detection kits (Roche) and a monoclonal antibody against a-sarcomeric actinin (a-SA; Sigma). 7 From the Masson's trichrome-stained images (HT15 Trichrome Stain kit; Sigma), viable tissue and scar area within the infarct region were measured on each section by tracing the infarct borders manually using the ImageJ software. Six sections were analysed per heart. Newly formed blood vessels were counted as SMA + /isolectin-IB4 2 (Sigma) structures under the microscope.
Statistical analysis
Unless otherwise stated, results are presented as means + SEM of n independent experiments. Statistical analyses were performed using InStat, version 3.0 (GraphPad Software, Inc.). The assumption that data were sampled from populations with identical SDs was tested using the method of Bartlett. One-way analysis of variance (ANOVA) with subsequent post hoc multiple comparison (Tukey-Kramer multiple comparisons test and Kruskal -Wallis test for parametric and non-parametric comparisons, respectively) was performed. Differences with a P-value of ,0.05 were considered statistically significant.
Results
Exosomes are the predominant component of EVs
Purified particles from CM-CPC using the ExoQuick TM method were studied by transmission electron microscopy and found to be 72.8 + 20.8 nm in diameter. Many of them exhibited bi-layer membranes ( Figure 1B -B I ) . Nanoparticle tracking analyses of purified EVs from CPCs using ExoQuick TM , ultracentrifugation, or Exo-spin TM revealed modal particle sizes (range; nm) of 73 nm (40-250), 85 nm (50 -400), and 68 nm (40-400), respectively ( Figure 1C -E Figure 1H ). Flow cytometric analyses of EVs secreted by CPCs revealed the expression of conventional exosomal markers (CD63, CD9, and CD81; Figure 1F and G) along with MSC/stromal markers (CD105, CD90, CD146, CD172, and NG2) also expressed Human exosomes preserve cardiac function after MI on parent CPCs (see Supplementary material online, Figure S1 ). Furthermore, dynamic trafficking of CD63 to exosomes was visualized in EVs secreted by CPCs transfected with the CD63-GFP vector (see Supplementary material online, Figure S2 ). Taken together, these results indicate that exosomes are the predominant component of EVs secreted by CPCs. With respect to the degrees of exosomal purity achieved by the three methods used, ExoQuick TM was comparable with, or slightly better than, ultracentrifugation and Exo-spin TM . However, a thorough comparison of purification methods was beyond the scope of this study.
EVs are the active component of CM-CPC
Anti-apoptotic activities of CM-CPC were assessed in the HL-1 cardiomyocytic cell line after 48 h of serum deprivation (Figure 2A) . CM-CPC added at 12 h reduced dead cells to 40 + 8% compared with 72 + 9% in the control group (P , 0.05; Figure 2B ). EV-depleted CM-CPC (DCM) did not reduce the number of dead cells (72 + 6%; NS). Reconstituting DCM with the previously removed EV fraction (DCM + EV) restored anti-apoptotic activity, reducing dead cells to 44 + 5% (P , 0.05 vs. BM). Similar changes were found in cells positive for activated caspase-3/7, a marker of programmed cell death activation ( Figure 2C) . Analogously, CM-CPC and DCM + EV, but not DCM, stimulated tube formation in HUVECs ( Figure 2D ). We then compared purified EVs secreted by CPCs with those secreted by fibroblasts. Only the former inhibited starvation-induced apoptosis in the HL-1 cardiomyocytic cell line, while stimulating tube formation in HUVECs (Figure 3 ). These results demonstrate that EVs are the active component of CM-CPC, and that functional activities of EVs depend on the parent cell type.
EVs secreted by CPCs are taken up by cardiomyocytes and impact on intracellular miRNA concentrations
Using laser confocal microscopy, we provided qualitative evidence that HL-1 cardiomyocytic cells take up DiI-labelled EVs secreted by CPCs ( Figure 4A-F ) . miRNA analyses revealed that miRNA-210 and miRNA-132 were among the most highly enriched miRNAs in EVs secreted by CPCs compared with those secreted by fibroblasts ( Figure 4G and see Supplementary material online, Figure S3 ). Incubation of these cells with EVs from CPCs resulted in a time and dose-dependent increase in the intracellular concentrations of miRNA-210 and miRNA-132 ( Figure 4H ). This observation plausibly reflects EV-mediated miRNA transfer to these cells.
EVs secreted by CPCs are enriched in miRNAs with anti-apoptotic and proangiogenic activities
miRNA transcriptional profiling of EVs secreted by CPCs or fibroblasts identified several miRNAs that were enriched in the former, such as miR-210, miR-132, miR-146a-3p, and miR-181 (see Supplementary material online, Figure S3 ). Functional roles were studied for two of them: miR-210 and miR-132. Both of these miRNAs inhibited apoptosis in HL-1 cardiomyocytic cells ( Figure 5A) . Conversely, transcriptional silencing of miR-210 exacerbated apoptosis (a similar trend was observed for miR-132). The effect of miR-210 was associated with functional downregulation of its known targets, ephrin A3 and PTP1, but not FLASH/ CASP8AP2 ( Figure 5B and C ) . miR-132 promoted tube formation in HUVECs ( Figure 5D ). This effect was associated with functional downregulation of its known target, RasGap-p120 ( Figure 5E and F ) . These results demonstrate that EVs secreted by CPCs are enriched in miRNAs with anti-apoptotic and proangiogenic activities. These miRNAs include miR-210 and miR-132.
EVs secreted by CPCs improve cardiac function after MI in vivo
Functional effects of EVs secreted by CPCs were assessed using an in vivo model of acute MI. Echocardiographic data are shown in Figure 6 . Heart rate was similar with all treatments (not shown). Each group of operated rats showed decreased LVEF, both at baseline and at 7 days, compared with sham-operated animals. LVEF at baseline was comparable in all groups except sham-operated animals. In PBS-injected hearts, LVEF significantly decreased from baseline to day 7. Infarcted hearts injected with either dosage of EVs secreted by CPCs, but not those injected with EVs secreted by fibroblasts, showed a higher LVEF at 7 days compared with the PBS-injected control group (P , 0.05). LVEF decreased from baseline to Day 7 in hearts injected with PBS, EV-F, or the lower dosage of EV-CPC, whereas it slightly increased in those injected with the higher dosage of EV-CPC (0.8 + 6.8 vs. 221.3 + 4.5% in the PBS group; P , 0.05). The increase in LV diameters observed by Day 7 in the PBS and EV-F groups was prevented by either dosage of EV-CPCs. Systolic LV wall thickening in the infarct border zone was enhanced with either dosage of EV-CPC (P , 0.05), but not with EV-F. These results indicate that EVs secreted by CPCs, but not those secreted by fibroblasts, improve cardiac function after MI.
EVs secreted by CPCs inhibit cardiomyocyte apoptosis, reduce scar, and promote angiogenesis after MI
We analysed the morphological consequences of EV injection on scarred areas, cardiomyocyte apoptosis, and blood vessel density in infarcted hearts. Histological analyses showed significantly larger areas of viable tissue in the infarct zone in hearts injected with the higher or lower dosage of EVs secreted by CPCs (41 + 8 and 32 + 5%, respectively), compared with those receiving EVs secreted by fibroblasts (24 + 1%; P , 0.05) or PBS control medium (23 + 2%; P , 0.05; Figure 7A and B). Reciprocally, scarred areas were decreased in hearts injected with the higher dosage of EVs from CPCs (59 + 8 vs. 77 + 2% in the PBS group; P , 0.05; Figure 7A and C). TUNEL-positive apoptotic cardiomyocytes were significantly decreased (P , 0.05; Figure 7D ), while blood vessel density being increased in hearts injected with EVs secreted by CPCs (84 + 13 vs. 34 + 5 vessel per mm 2 in the PBS group; P , 0.01; Figure 7E ). These findings demonstrate structural benefits of EVs secreted by CPCs and delivered to injured hearts in vivo.
Discussion
Recent evidence suggests that CPC transplantation into damaged hearts may be beneficial, and that indirect mechanisms may be responsible for most of the therapeutic benefit. Because EVs are increasingly emerging as the active component of the paracrine secretion by various cell types, 17, 18 we have investigated their potential role as mediators of the cardioprotective effect of human CPCs. Here, we show that EVs fully account for the cardioprotective and proangiogenic paracrine activities of human CPCs. Indeed, CM-CPC depleted of EVs lacked these activities, which were recapitulated by purified EVs. This observation would imply negligible roles for soluble factors secreted by CPCs, such as growth factors and cytokines, which are not encapsulated in membrane vesicles, possibly due to enzymatic degradation in the extracellular compartment. In contrast, membrane vesicles protect their cargoes and deliver them to recipient cells.
Collectively, transmission electron microscopy, nanoparticle tracking analysis, and surface antigen expression data indicated that the purified particles from human CPCs predominantly consists of exosomes. Taking into account the presence of particles .90 nm in diameter in the purified preparations, however, we refer to them as EVs, which encompasses both exosomal and non-exosomal EVs. It should be stressed that many studies of 'exosomes' have actually used heterogeneous EV populations. One notable exception was the study by Lai et al., 18 who purified exosomes secreted by MSCs as a homogeneous population of particles with a hydrodynamic radius of 55-65 nm by size-exclusion fractionation on a HPLC. These particles reduced infarct size in an ex vivo mouse Langendorff heart model of myocardial ischaemia/reperfusion injury. When injected into the infarct border zone in vivo, purified EVs secreted by CPCs mitigated cardiomyocyte apoptosis, augmented blood vessel density, reduced scar while increasing viable areas in the infarct zone, and improved cardiac function compared with hearts injected with control medium. In contrast, purified EVs secreted by dermal fibroblasts lacked therapeutic benefits, illustrating the critical role of the parent cell. These findings are in line with, and expand, the aforementioned data by Lai et al. 18 on exosomes secreted by MSCs, as well as data by Chen et al., 19 showing anti-apoptotic activity of exosomes secreted by mouse CPCs in a myocardial model of ischaemia/ reperfusion injury. EVs secreted by CPCs were enriched in several miRNAs including miR-210, miR-132, and miR-146a-3p compared with those secreted by fibroblasts. Both miR-210 and miR-132 inhibited apoptosis in the HL-1 cardiomyocytic cell line in vitro. This effect of miR-210 was associated with functional down-regulation of its validated targets, ephrin A3 and PTP1, but not of FLASH/CASP8AP2. These results are in line with previous findings. 21 Moreover, miR-132 stimulated tube formation in HUVECs. This effect was associated with functional down-regulation of the known miR-132 target, RasGap-p120. This observation is in agreement with previous data. 22 We also documented dose-and time-dependent increases in the intracellular concentrations of miR-210 and miR-132 after exposure of the HL-1 cardiomyocytic cell line to EVs secreted by CPCs. This finding shows that purified donor EVs can modify miRNA concentrations in recipient cardiomyocytes. miRNA transfer therefore appears to be a plausible mechanism for the therapeutic benefit of EVs. (white arrows indicate systolic anterior wall thickening in EV-CPC -injected hearts). Changes in LVEF from baseline to Day 7 were negative in all groups, but in hearts injected with the higher dosage (HD) in EV-CPC (LD, lower dosage; LVEDD/LVESD, LV end-diastolic/end-systolic diameter; LVEDTHK-BZ, LV end-diastolic wall thickness; LVESTK-BZ, end-systolic wall thickening in the border zone; mean + SEM; PBS, n ¼ 9; 30 mg EV-CPC LD, n ¼ 9; 300 mg EV-CPC HD, n ¼ 10; 300 mg Exo-F, n ¼ 4; sham, n ¼ 9; *P , 0.05 vs. PBS; # P , 0.05 at Day 7 vs. baseline; As cell-free products, EVs including exosomes may have a potential for circumventing many of the limitations of using replicating cells as therapeutic agents. 29 Indeed, secreted vesicles may be easier to manufacture and standardize in terms of dosage and biological activity compared with their parent cells. Exosomes are stable during storage at 2208C, and their size is unaffected by multiple freezing to 2208C and thawing, whereas it decreases at 4 and 378C, indicating structural changes or degradation. 30 After all, there may be no interest in transplanting cells that essentially act through their paracrine secretion. Further studies are needed to address long-term effects of exosome therapy for damaged hearts and whether allogeneic cells could be used as EV donors for clinical use.
In conclusion, we have demonstrated that EVs are the active component of the paracrine secretion by human CPCs, are enriched in miRNAs with anti-apoptotic and proangiogenic activities, and can improve cardiac function after MI.
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